For Massachusetts-based Lantheus, the deal comes after the merger with Progenics in 2020 that formed the backbone of its radio-oncology franchise, which was extended last year with the acquisition ...

Q3 2024 Earnings Call Transcript November 6, 2024 Lantheus Holdings, Inc. beats earnings expectations. Reported EPS is $1.79, ...

Molecular Insight was subsequently acquired by Progenics in 2013, who oversaw the completion of clinical testing and development of the drug. Unlike LSA-MIBG, HSA-MIBG was subjected to the ...

Efstathiou reported consulting fees or honoraria from Blue Earth Diagnostics, Boston Scientific, AstraZeneca, Genentech, ...

His non-academic experiences include working for Goldman, Sachs & Co., being the President of Progenics Pharmaceuticals, Inc. a start-up biotechnology company, and being the director of economics for ...

PYLARIFY has made a profound impact on the lives of patients battling prostate cancer. It is the number one ordered PSMA PET imaging agent in the U.S., and is a proven diagnostic backed by real-world ...

“These tumours are ultra rare, and it is simply not feasible to run a clinical trial involving hundreds of patients,” says Vivien Wong, executive vice president of R&D at Progenics ...

Welcome to the Lantheus Third Quarter 2024 Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's ...